Member Info for JOHNO77

One of Nuvec's key advertised USP'S has always been its advantages over lipid based delivery systems.

I think Tony will be pushing as hard as he can. He's also commited to obtaining a valuation for Satoshipay this year so value should be attributed at some point. I am sure he 'll be waiting for the best market conditions in which to conduct any Satoshipay 'sale' process.

Hold for gold

PEN is more pen & ink at the mo. Be good for Pendulum to gain traction once more.

Nice to get an update although Dynasty should also be providing more of an overall progress report to Blu at this stage so that it can be rns'ed.

What a result.

Nice work LBE, happy days.

Nice info Hall.
Things definitely looking up for N4P.

No bad news there and signs of green shoots. Positve language from Ensor who can take this company forward again. Not a bad looking entry from 1.25p 1.6m cap levels...

Have re-read the rns a few times, it sounds better each time i read it. As Brighty has said, these are big boys supplying the Venetoclax (Roche) and Gefitinib (AZN) drugs.

For Nuvec to have initial comparable findings delivering EGFR and BCl-2 compared to their own offerings is excellent news. If subsequent tests continue to show that Nuvec can deliver, including dual loading, then it bodes very well for N4's partnership potential.

Much better news for N4P this morning! I'm sure i posted this morning have some posts been deleted?

Onwards and upwards!

GLALTH's

A trade has just gone through at 11.28:

https://www.mexc.com/exchange/PENDULUM_USDT?_from=search_spot_trade

Matina's association with BioNTech is the kind of deal N4 has needed for years. Hopefully something similar will arrive soon.

Have you bought back in here again Stille?

Nice to see positive movement today.

Gave his details to someone he shouldn't have trusted...

What a muppet........

TY Duke

Why do you think Dynasty news by end of next week Duke??

Let's hope it's a premonition lol

Cheers Leister

As Nigel stated in the latest directors talk interview, their should be multiple items of newsflow to come before the end of June.

siRNA results as they come in for both single loading, double loading ,in-vitro and in-vivo.

The target market for commercial discussions also now much larger with the focus on siRNA as opposed to just vaccine delivery.

Plus the sidelines of oral delivery / viral vectors / gene therapy...

Obviously existing investors have had a rough time but for new investors suddenly it's not looking so bad. 1.7p doesn't look like a bad entry considering the co recently cashed themselves up via the 2p placing.

Dysentery need to step up to the plate!

Maybe at the AGM they should have issued long service awards to us shareholders... lol.

https://twitter.com/pendulum_chain/status/1641803674371473409?s=12